Strategy & Partnerships$TEM

Tempus AI signs $200 million AstraZeneca commitment through 2031

AstraZeneca committed to $200 million in fees payable to Tempus AI through Dec. 31, 2031, under an amended master services agreement. The amendment takes effect Jan. 1, 2027, with an annual target of $40 million.

Key takeaways

  • Tempus AI (TEM) and AstraZeneca AB agreed to a fifth amendment to their master services agreement, effective Jan. 1, 2027. AstraZeneca committed to $200 million in fees through Dec. 31, 2031, with a $32 million annual minimum. The term may extend to 2032 if the commitment is not met.
Tempus AI logo

Tempus AI (TEM) and AstraZeneca AB agreed to a fifth amendment to their master services agreement, effective Jan. 1, 2027.

Shares rose 1.4% at 9:36 a.m. ET, from a $63.43 close.

The amendment sets a new five-year financial commitment period and extends the term through Dec. 31, 2031. AstraZeneca has committed to $200 million in fees payable to Tempus AI under the agreement and other contracts between the parties and their affiliates during the renewal term, an annual target of $40 million across existing and future products and services. It also requires a minimum of $32 million in fees in each calendar year of the renewal term.

The amendment also extends the strategic collaborator benefits AstraZeneca receives under the existing agreement.

If the $200 million commitment is not met by the end of the renewal term, the term extends one year, through Dec. 31, 2032, to address the shortfall.

AstraZeneca may still end the agreement for convenience at any time. If it does and has not fulfilled its financial commitments by that date, it will owe Tempus AI any shortfall against the $200 million commitment.

Sources